BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Phase 3
Active, not recruiting
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1011
- Registration Number
- NCT04423718
- Locations
- 🇧🇬
SEHAT Pentagram, Sofia, Bulgaria
🇧🇬University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD, Sofia, Bulgaria
🇺🇸Arizona Retina and Vitreous Consultants - North Phoenix, Phoenix, Arizona, United States
This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)
Phase 2
Terminated
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Drug: BAY1097761 Active Dose 1Drug: BAY1097761 Active Dose 2Other: Placebo to BAY1097761
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 90
- Registration Number
- NCT04417036
- Locations
- 🇪🇸
Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain
🇪🇸Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain
🇨🇿Fakultni nemocnice v Motole, Praha 5, Czechia
A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs
Completed
- Conditions
- Coronary Artery DiseasePeripheral Artery Disease
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3189
- Registration Number
- NCT04401761
- Locations
- 🇨🇳
Many Locations, Multiple Locations, Taiwan
Study to Learn More About Outcomes Reported by Patients Suffering From Type 2 Diabetes Using a Digital Data Collection Tool
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: No intervention
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT04383041
- Locations
- 🇩🇪
Many locations, Multiple Locations, Germany
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT04366622
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT04364464
Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
Completed
- Conditions
- Non-valvular Atrial Fibrillation (NVAF)
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 493
- Registration Number
- NCT04356989
- Locations
- 🇨🇳
Many Locations, Multiple Locations, Taiwan
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT04356339
- Locations
- 🇺🇸
myBETAapp, Whippany, New Jersey, United States
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Phase 1
Terminated
- Conditions
- Pharmacology, Clinical
- Interventions
- Drug: Neladenoson bialanate (BAY 1067197)
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 22
- Registration Number
- NCT04322253
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Phase 1
Terminated
- Conditions
- Pharmacology, Clinical
- Interventions
- Drug: Neladenoson bialanate (BAY 1067197)
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT04320771
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
🇩🇪APEX GmbH, München, Bayern, Germany
© Copyright 2025. All Rights Reserved by MedPath